This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
10 mg/kg or 20 mg/kg administered intravenously Q3w
15 mg/kg administered intravenously Q3w
200 mg administered intravenously Q3w
West China Hospital of Sichuan University
Chengdu, Sichuan, China
RECRUITINGprogression free survival，PFS
defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first.
Time frame: through study completion, up to 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
15 mg/kg administered intravenously Q3w